Key Highlights

  • Starpharma is undertaking a fully underwritten renounceable entitlement offer to raise approximately $32 million, issuing approximately 56 million new shares at $0.57 per share on a one-for-7.5 basis.
  • The offer price represents a 25% discount to the last closing price of $0.76 and a 22% discount to the Theoretical Ex Rights Price of $0.73, with Canaccord Genuity acting as lead manager and underwriter.
  • Proceeds are intended to fund the first-in-human and dose escalation stages of the DEP HER2-Lu Phase 1 study, develop novel dendrimer-based oncology assets and extend the cash runway into FY28.
  • The raising follows recent announcements regarding the application of Starpharma’s dendrimer technology in radioligand therapy across a range of oncology targets, highlighting the potential breadth of the DEP platform.

Starpharma Holdings Limited (ASX:SPL) announced on 15 July 2026 that it is undertaking a fully underwritten renounceable entitlement offer to raise approximately $32 million in gross proceeds. The offer is structured as one new share for every 7.5 existing shares at $0.57 per new share, with Canaccord Genuity acting as lead manager and underwriter. The proceeds are directed primarily toward advancing the company’s dendrimer-enhanced drug delivery program in oncology, specifically the DEP HER2-Lu radioligand therapy asset.

The announcement accompanies a period of increased investor attention on Starpharma’s dendrimer technology platform following disclosures about its potential applications in radioligand therapy across multiple oncology targets.

The DEP HER2-Lu Program: Rationale and Focus

The primary use of proceeds is to fund the first-in-human and dose escalation stages of the DEP HER2-Lu Phase 1 study. HER2-Lu refers to the combination of a HER2-targeting agent with a lutetium radioisotope, structured as a radioligand therapy — a class of cancer treatment that uses a targeting molecule to deliver radiation directly to cancer cells expressing specific surface proteins.

Starpharma’s DEP (dendrimer enhanced product) platform wraps active pharmaceutical ingredients in dendrimer nanostructures to alter their pharmacokinetic and pharmacodynamic properties. In the context of radioligand therapy, the company’s recent disclosures have highlighted preclinical data suggesting that dendrimer encapsulation may improve the delivery and distribution of radioligand therapies, potentially differentiating its assets from other HER2-targeted radioligand approaches.

CEO Cheryl Maley described the DEP HER2-Lu program as reflecting the potential of dendrimer technology in radioligand therapy, citing recent preclinical data as supporting the company’s broader strategy to develop a pipeline of novel targeted dendrimer oncology assets.

Capital Structure and Offer Mechanics

The entitlement offer is renounceable, meaning eligible shareholders who do not wish to participate in the raising can sell or transfer their entitlements rather than simply allowing them to lapse. The offer is structured on a one-for-7.5 basis at $0.57 per new share, raising approximately $32 million in gross proceeds. The offer price represents a 25% discount to the last traded closing price of $0.76 and a 22% discount to the Theoretical Ex Rights Price.

Eligible shareholders include those with registered addresses in Australia, New Zealand, Hong Kong, Singapore, the United Kingdom or Luxembourg. Shareholders who take up their full entitlement may also apply for additional new shares up to 100% of their existing entitlement via an oversubscription facility, subject to availability and scale-back at the board’s discretion.

The offer is fully underwritten by Canaccord Genuity, meaning that any shortfall from shareholders who do not participate will be placed with institutional investors, providing certainty over the gross proceeds regardless of the participation rate.

Cash Runway and FY28 Extension

The proceeds from the raise are expected to extend Starpharma’s cash runway into FY28. A pro forma 30 June 2026 cash balance of $44.5 million is referenced, incorporating the expected $3.5 million research and development tax incentive. This runway extension is described as providing the capital required to progress the DEP HER2-Lu Phase 1 study alongside the broader development of additional dendrimer oncology assets.

Starpharma’s existing commercialised products — three over-the-counter products marketed under separate brands — generate revenue that partially offsets the operating cost base, differentiating the company from entirely pre-revenue biotechnology companies. However, the core investment thesis rests on the progression of the DEP clinical pipeline toward regulatory approval and commercialisation.

Indicative Timetable

The offer process is structured to conclude in August 2026. Key dates include the ex date on 17 July, the record date of 20 July, offer documents dispatched from 23 July, and the offer closing date of 4 August. New shares are expected to be issued on 11 August with trading commencing on 12 August.

The announcement was preceded by a trading halt pending the capital raising, with the offer booklet to be lodged with the ASX and dispatched to eligible shareholders following the announcement. The offer is made without a prospectus under section 708AA of the Corporations Act 2001.

 

Conclusion

Starpharma’s $32 million entitlement offer positions the company to progress its DEP HER2-Lu Phase 1 study into first-in-human dosing while simultaneously broadening its oncology pipeline. The fully underwritten structure provides certainty over the funding outcome, and the FY28 runway extension removes near-term capital uncertainty. The commercial and clinical trajectory of the DEP platform — particularly the radioligand therapy applications highlighted in recent disclosures — will be the primary determinant of whether the capital raised translates into durable shareholder value over the period ahead.